Haisco Pharmaceutical Group Co (SZSE:002653) Accounts Payable & Accrued Expense : ¥368 Mil (As of Mar. 2024)

View and export this data going back to 2012. Start your Free Trial

What is Haisco Pharmaceutical Group Co Accounts Payable & Accrued Expense?

Haisco Pharmaceutical Group Co's quarterly accounts payable & accrued expense increased from Sep. 2023 (¥317 Mil) to Dec. 2023 (¥543 Mil) but then declined from Dec. 2023 (¥543 Mil) to Mar. 2024 (¥368 Mil).

Haisco Pharmaceutical Group Co's annual accounts payable & accrued expense declined from Dec. 2021 (¥539 Mil) to Dec. 2022 (¥499 Mil) but then increased from Dec. 2022 (¥499 Mil) to Dec. 2023 (¥543 Mil).

Haisco Pharmaceutical Group Co Accounts Payable & Accrued Expense Historical Data

The historical data trend for Haisco Pharmaceutical Group Co's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Haisco Pharmaceutical Group Co Accounts Payable & Accrued Expense Chart

Haisco Pharmaceutical Group Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

981.63

689.76

539.40

499.02

542.56

Haisco Pharmaceutical Group Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															336.94	317.56	316.67	542.56	367.76

Haisco Pharmaceutical Group Co Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Haisco Pharmaceutical Group Co (SZSE:002653) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Haisco Pharmaceutical Group Co Ltd (SZSE:002653) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 17, Sanxiang Avenue, Shannan District, Tibet Autonomous Region, Zetang, CHN, 856000

Website

http://www.haisco.com

Haisco Pharmaceutical Group Co Ltd is a pharmaceutical company based in China. It is mainly engaged in the research, development, manufacture, and sale of drugs for liver disease. Its product portfolio includes parenteral nutrition drugs, antibiotics, anesthetic agents, digestive system drugs and tumour adjuvant drug series. The company's products are being used in first rank hospitals in China.

Executives

Fan Xiu Lian	Directors, executives
Zheng Wei	Directors, executives
Wang Meng	Secretary Dong
Wang Jun Min	Directors, executives
Deng Xiang	Directors, executives
Liu Han Bing	Supervisors
Zhang Xiao Xu	Supervisors
Tan Hong	Executives
Shen Ping	Director
Liang Yong	Supervisors
Chen Long	Independent director
Duan Qing Liang	Supervisors

Haisco Pharmaceutical Group Co (SZSE:002653) Headlines

No Headlines